Although adjuvant olaparib has been shown to improve survival in patients with BRCA1/2-mutated breast cancer, there is a paucity of evidence regarding its safety when combined with radiation therapy, which generates a significant amount of DNA damage.3 The gene discussed is BRCA1; the disease is breast carcinoma.